Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging

被引:8
|
作者
Monkman, James [1 ]
Moradi, Afshin [1 ]
Yunis, Joseph [1 ,2 ]
Ivison, Geoff [3 ]
Mayer, Aaron [3 ]
Ladwa, Rahul [4 ]
O'Byrne, Ken [4 ]
Kulasinghe, Arutha [1 ]
机构
[1] Univ Queensland, Frazer Inst, Fac Med, 37 Kent St, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Fac Med, Ian Frazer Ctr Childrens Immunotherapy Res, Childrens Hlth Res Ctr, Brisbane, Qld, Australia
[3] Enable Med, Menlo Pk, CA USA
[4] Princess Alexandra Hosp, Brisbane, Qld, Australia
关键词
IMMUNITY;
D O I
10.1186/s12967-024-05035-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The spatial localisation of immune cells within tumours are key to understand the intercellular communications that can dictate clinical outcomes. Here, we demonstrate an analysis pipeline for highly multiplexed CODEX data to phenotype and profile spatial features and interactions in NSCLC patients that subsequently received PD1 axis immunotherapy. We found that regulatory T cells (Tregs) are enriched in non-responding patients and this was consistent with their localization within stromal and peripheral tumour-margins. Proximity-based interactions between Tregs and both monocytes (p = 0.009) and CD8+ T cells (p = 0.009) were more frequently found in non-responding patients, while macrophages were more frequently located in proximity to HLADR+ tumour cells (p = 0.01) within responding patients. Cellular neighbourhoods analysis indicated that both macrophages (p = 0.003) and effector CD4+ T cells (p = 0.01) in mixed tumour neighbourhoods, as well as CD8+ T cells (p = 0.03) in HLADR+ tumour neighbourhoods were associated with favorable clinical response. Evaluation of the inferred regulatory functions between immune cells relative to the tumour suggested that macrophages exhibit an immunosuppressive phenotype against both CD4+ and CD8+ T cells, and that this association scores more highly in ICI refractory patients. These spatial patterns are associated with overall survival in addition to ICI response and may thus indicate features for the functional understanding of the tumour microenvironment.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [42] Eicosanoids in non-small cell lung cancer (NSCLC)
    Johnson, D. H.
    Horn, L.
    Zhao, Z.
    Milne, G.
    Morrow, J.
    Sandler, A.
    Shyr, Y.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
    Christian Manegold
    Petr Zatloukal
    Kurt Krejcy
    Johannes Blatter
    Investigational New Drugs, 2000, 18 : 29 - 42
  • [44] BRCAness in non-small cell lung cancer (NSCLC).
    Waqar, Saiama Naheed
    Devarakonda, Siddhartha H. K.
    Michel, Loren S.
    Maggi, Leonard B.
    Watson, Mark
    Guebert, Kalin
    Carpenter, Danielle
    Sleckman, Barry P.
    Govindan, Ramaswamy
    Morgensztern, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [46] Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Schmid, S.
    Diem, S.
    Krapf, M.
    Li, Q.
    Flatz, L.
    Leschka, S.
    Desbiolles, L.
    Klingbiel, D.
    Jochum, W.
    Fruh, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2420
  • [47] Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer
    Shroff, Girish S.
    Strange, Chad D.
    Ahuja, Jitesh
    Altan, Mehmet
    Sheshadri, Ajay
    Unlu, Ebru
    Truong, Mylene T.
    Vlahos, Ioannis
    RADIOGRAPHICS, 2022, 42 (07) : 1956 - 1974
  • [48] Biomarkers of immunotherapy for non-small cell lung cancer
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 13 - 22
  • [49] Perioperative Immunotherapy in Non-Small Cell Lung Cancer
    Jenny O’Brien
    J. Nicholas Bodor
    Current Treatment Options in Oncology, 2023, 24 : 1790 - 1801
  • [50] Principles of Immunotherapy in Non-Small Cell Lung Cancer
    Hsu, Melinda L.
    Naidoo, Jarushka
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 187 - +